sutures newsletter


Mark Your Calendar

Surgery Grand Rounds

Click the "read more" to see information about upcoming Surgery Grand Rounds.

Grand Rounds

Click here to view a schedule of all upcoming grand rounds.

Education Schedule

Click the PDF links below to see the Department of Surgery's education schedule.

Education Schedule - April 2015 (PDF)

Surgery Scheduling

Click the "read more" for hours and contact information for surgery scheduling.

Share Your News

Know an interesting colleague we should profile? A story we should tell? Submit your ideas, meetings and events for consideration.

Click here to submit your news to Sutures

Sofosbuvir, Feraheme Warnings; Changes for Epivir, Ziagen

Pharmacy Focus

The U.S. Food and Drug Administration has issued warnings about hepatitis C drugs containing sofosbuvir and has strengthened a warning about Feraheme. The agency also has approved changes in the labels of Epivir and Ziagen.

FDA: Sofosbuvir/Amiodarone Combination Can Lead to Bradycardia

The FDA is recommending that drugs containing sofosbuvir, such as Sovaldi and Harvona, not be prescribed concurrently with the antiarrhythmic drug amiodarone. Bradycardia — serious slowing of the heart rate — can occur when the drugs are taken together, according to the FDA. If alternative treatment options are unavailable, the FDA recommends heart monitoring in an inpatient hospital setting for the first 48 hours. Subsequently, monitoring in a doctor’s office or self-monitoring of the heart rate should take place every day through at least the first two weeks of treatment.

For more information, click here.

FDA: Serious Reactions Possible with Feraheme

The FDA has strengthened a warning that serious, potentially fatal allergic reactions can occur with the anemia drug Feraheme (ferumoxytol). The FDA changed the prescribing instructions and approved a boxed warning, the agency's strongest type of warning, regarding these risks. Also added is a strong recommendation against use of Feraheme in patients who have had an allergic reaction to any intravenous iron replacement product.

For more information, click here.

FDA Backs Changes in Labels of Epivir, Ziagen

The FDA has approved revisions to the labels for Epivir (lamivudine) and Ziagen (abacavir sulfate) to provide for once-daily dosing in pediatric patients 3 months and older when used in combination with other antiretrovirals for the treatment of HIV-1 infection.

For more information, click here or on the PDF links below.

Epivir package insert (PDF)

Ziagen package insert (PDF)